- Home
- GDV vs CGON Comparison
GDV vs CGON Comparison
Compare GDV & CGON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDV
- CGON
- Stock Information
- Founded
- GDV 2003
- CGON 2010
- Country
- GDV United States
- CGON United States
- Employees
- GDV N/A
- CGON N/A
- Industry
- GDV Investment Managers
- CGON
- Sector
- GDV Finance
- CGON
- Exchange
- GDV Nasdaq
- CGON NYSE
- Market Cap
- GDV 2.3B
- CGON 2.3B
- IPO Year
- GDV N/A
- CGON 2024
- Fundamental
- Price
- GDV $24.81
- CGON $29.08
- Analyst Decision
- GDV
- CGON Strong Buy
- Analyst Count
- GDV 0
- CGON 10
- Target Price
- GDV N/A
- CGON $65.11
- AVG Volume (30 Days)
- GDV 186.0K
- CGON 809.2K
- Earning Date
- GDV 01-01-0001
- CGON 02-02-2025
- Dividend Yield
- GDV 5.81%
- CGON N/A
- EPS Growth
- GDV N/A
- CGON N/A
- EPS
- GDV N/A
- CGON N/A
- Revenue
- GDV N/A
- CGON $684,000.00
- Revenue This Year
- GDV N/A
- CGON $210.00
- Revenue Next Year
- GDV N/A
- CGON N/A
- P/E Ratio
- GDV N/A
- CGON N/A
- Revenue Growth
- GDV N/A
- CGON 258.12
- 52 Week Low
- GDV $18.04
- CGON $25.77
- 52 Week High
- GDV $23.00
- CGON $50.23
- Technical
- Relative Strength Index (RSI)
- GDV 57.35
- CGON 44.86
- Support Level
- GDV $23.73
- CGON $27.70
- Resistance Level
- GDV $24.49
- CGON $29.69
- Average True Range (ATR)
- GDV 0.28
- CGON 1.43
- MACD
- GDV 0.08
- CGON 0.16
- Stochastic Oscillator
- GDV 93.91
- CGON 31.29
About GDV Gabelli Dividend & Income Trust of Beneficial Interest
Gabelli Dividend & Income Trust operates as a diversified closed-end management investment company. The fund's investment objective is to provide a high level of total return on its assets with an emphasis on dividends and income. To achieve its objective, the fund may invest its assets in dividend-paying securities or other income-producing securities. The fund invests in various sectors, in which Financial Services, Food & Beverage, Health Care, Consumer Products, Electronics, and Computer Software & Services and others.
About CGON CG ONCOLOGY INC
CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.